Abstract Two sisters (ages 16 yr and 15 yr) have been followed by our clinical genetics team for several years. Both girls have severe intellectual disability, hypotonia, seizures, and distinctive craniofacial features. The parents are healthy and have no other children.
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Ontology terms: absent speech; aplasia/hypoplasia of the corpus callosum; autism; broad nasal tip; cleft of chin; clinodactyly of the 5th finger; downslanted palpebral fissures; generalized hirsutism; high forehead; high, narrow palate; hypertelorism; incisor macrodontia; intellectual disability, severe; prominent nasal bridge; recurrent hand flapping; severe global developmental delay; severe muscular hypotonia; short stature; thick eyebrow 
TECHNICAL ANALYSIS AND METHODS
The proband, her affected sibling, and both parents underwent exome sequencing as follows. Exome capture was performed using Agilent SureSelect v5 reagents according to manufacturer protocols. Exome libraries underwent paired-end sequencing (2 × 100 bp) on an Illumina HiSeq 2500 instrument. We generated ∼6.2 Gbp of uniquely mapped reads per sample (Table 2) . Reads were mapped to the GRCh37 reference sequence and secondary data analysis was performed using Churchill (Kelly et al. 2015) , which implements the GATK "best practices" workflow for alignment, variant discovery and genotyping. Sequencing metrics are provided in Supplemental Table 1 . Variants were called in all four Table 2 ; Manichaikul et al. 2010) . SNPeff, ANNOVAR, and custom in-house scripts were used to annotate SNPs/indels with gene, transcript, function class, damaging scores, and population allele frequencies. Some 32,095 variants mapped to the exons or splice regions of known protein-coding genes. After removing common variants (MAF > 0.01 in the ExAC, ESP, or 1000 Genomes databases), we selected for further analysis all splice site, frameshift, and nonsense variants, as well as missense variants predicted to be damaging by SIFT (score < 0.05), PolyPhen (score > 0.453), GERP (score > 2.0), or CADD (Phred score > 15).
We searched for variants consistent with recessive inheritance that were present in both patients, finding no compound-heterozygous variants but two homozygous recessive variants of uncertain significance (described in the Supplemental Text and Supplemental Table 3 ). We also searched for candidate de novo mutations and identified a candidate nonsense mutation at the same position in both patients.
VARIANT INTERPRETATION
A heterozygous nonsense variant in ASXL3 (Table 3 ) was present in both sisters but absent from the parents. Manual review of the exome data verified the variant in both patients but showed no evidence of the alternate allele in either parent (Supplemental Fig. 1 ). The de novo status was independently confirmed by Sanger sequencing of all four individuals (Supplemental Fig. 2) .
The variant is predicted to cause a stop-gain at amino acid 1036 (NM_030632.1 c.3106C>T, p.R1036X), at ∼46% of its wild-type length (Fig. 1A) . It has never been observed in 122,882 individuals in the gnomAD database, making it extremely rare in human populations. However, truncating mutations in ASXL3 were recently reported as the cause of Bainbridge-Ropers syndrome (BRPS, OMIM #615485), a disorder similar to Bohring-Opitz syndrome, which is caused by truncating mutations in ASXL1 (Bainbridge et al. 2013) .
The Human Gene Mutation Database (HGMD) contains 10 nonsense/frameshift ASXL3 variants (five nonsense variants and five frameshift indels) reported in patients with Bainbridge-Ropers syndrome or Bohring-Opitz-like syndrome (Fig. 1B) . The ClinVar database contains 22 nonsense/frameshift variants (12 nonsense variants including p.R1036X, and 10 frameshift indels), all of which are reported as Pathogenic or Likely Pathogenic (Fig.  1C) . Of note, many of the pathogenic mutations reported in ASXL1 in Bohring-Opitz syndrome also truncate ∼50% of the encoded protein (Fig. 1D) . Constraint metrics from the ExAC database (Lek et al. 2016) likewise indicate that ASXL3 is extremely intolerant of lossof-function (LoF) mutations (43.1 variants expected, 3 observed, pLI = 1.00; Fig. 1E ). Criteria: PVS1, null variant; PS2, de novo in a patient with disease and no family history; PM2, absent from population controls; PP1, cosegregation with disease in a gene definitively known to cause the disease; PP5, reputable source recently reports the variant as pathogenic, but evidence was not available for us to perform an independent evaluation.
ASXL3 mutation in Bainbridge-Ropers syndrome C O L D S P R I N G H A R B O R

Molecular Case Studies
In summary, this de novo nonsense mutation is present in both affected individuals, absent from databases of population controls, and consistent with previously reported pathogenic mutations in ASXL3. We therefore conclude that it is pathogenic, and we provide a molecular diagnosis of Bainbridge-Ropers syndrome to the proband and her affected sibling.
SUMMARY
Bainbridge-Ropers syndrome (BRPS) was first described in 2013, when Bainbridge et al. reported de novo truncating mutations in four unrelated probands with feeding difficulties, failure to thrive, neurological abnormalities, and significant developmental delay. To date, fewer than 30 cases of BRPS have been described in the literature (Bainbridge et al. 2013; Dinwiddie et al. 2013; Srivastava et al. 2016; Balasubramanian et al. 2017; Kuechler et al. 2017) . The report by Kuechler et al. includes a 4-yr old female with the p.R1036X mutation. She was not reported to have seizures (Supplemental Table 4 ), but she and both of our patients share the six most emerging hallmarks of BRPS: severe intellectual disability, poor/absent speech, autistic traits, distinct face, hypotonia, and significant feeding difficulties. We assess our patients for the clinical features highlighted by Balasubramanian et al. (2017) in Supplemental Table 5 .
We recently diagnosed a third (unrelated) child at our institution, suggesting that the prevalence of BRPS is likely to be higher than currently reported in the medical literature, and the diagnosis will be made more frequently as WES is incorporated more routinely into clinical practice. Indeed, the membership of a support group for BRPS families suggests that as many as 200 patients may have been diagnosed to date (M Bainbridge, pers. comm.) .
To our knowledge, this is the first report of BRPS caused by the same de novo mutation in two related individuals (siblings). Although it is theoretically possible that the same mutation 
ADDITIONAL INFORMATION Data Deposition and Access
The ASXL3 variant and information about its interpretation were submitted to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) on September 29, 2017 (SCV000605939) and accepted/released on October 9, 2017. Unfortunately, the informed consent does not allow for deposition of the raw sequencing data into public databases.
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